"
Team:Potsdam Bioware
From 2011.igem.org
| Line 2: | Line 2: | ||
<html> | <html> | ||
| - | <div class="div_home" onClick="window.open(' | + | <div class="div_home" onClick="window.open('https://2011.igem.org/Team:Potsdam_Bioware/Project','_self');"> |
<p> | <p> | ||
| Line 15: | Line 15: | ||
<!---Box on the upper left: Software---> | <!---Box on the upper left: Software---> | ||
| - | <div class="box_home"> | + | <div class="box_home" onClick="window.open('https://2011.igem.org/Team:Potsdam_Bioware/Software','_self');"> |
<h2>Software</h2> | <h2>Software</h2> | ||
<p> | <p> | ||
| Line 23: | Line 23: | ||
<!---Small box on the right: Team | <!---Small box on the right: Team | ||
| - | <div class="box_long"> | + | <div class="box_long" onClick="window.open('https://2011.igem.org/Team:Potsdam_Bioware/Team,'_self');"> |
<h2>Team</h2> | <h2>Team</h2> | ||
<p> | <p> | ||
| Line 164: | Line 164: | ||
<!---Box on the upper right: BioBricks---> | <!---Box on the upper right: BioBricks---> | ||
| - | <div height="290px"> | + | <div height="290px" onClick="window.open('https://2011.igem.org/Team:Potsdam_Bioware/BioBricks','_self');"> |
<div class="box_home_small"> | <div class="box_home_small"> | ||
<h2>BioBricks</h2> | <h2>BioBricks</h2> | ||
| Line 171: | Line 171: | ||
<!---Box on the lower left: Human Practice---> | <!---Box on the lower left: Human Practice---> | ||
| - | <div class="box_home_small"> | + | <div class="box_home_small" onClick="window.open('https://2011.igem.org/Team:Potsdam_Bioware/Safety_Ethics','_self');"> |
<h2>Human Practice</h2></a> | <h2>Human Practice</h2></a> | ||
<p class="standard">Lorem ipsum dolor sit amet, consetetur sadipscing elitr, sed diam nonumy eirmod tempor invidunt ut labore et dolore magna aliquyam erat, sed diam voluptua. <a href="https://2011.igem.org/Team:Potsdam_Bioware/Safety_ethics"><span class="bold">[more]</span></a></p> | <p class="standard">Lorem ipsum dolor sit amet, consetetur sadipscing elitr, sed diam nonumy eirmod tempor invidunt ut labore et dolore magna aliquyam erat, sed diam voluptua. <a href="https://2011.igem.org/Team:Potsdam_Bioware/Safety_ethics"><span class="bold">[more]</span></a></p> | ||
| Line 177: | Line 177: | ||
<!---Box on the lower right: labjournal---> | <!---Box on the lower right: labjournal---> | ||
| - | <div class="box_home_small"> | + | <div class="box_home_small" onClick="window.open('https://2011.igem.org/Team:Potsdam_Bioware/Labjournal','_self');"> |
<h2>Labjournal</h2> | <h2>Labjournal</h2> | ||
<p> | <p> | ||
| Line 184: | Line 184: | ||
<!---Box on the lower right: Modelling---> | <!---Box on the lower right: Modelling---> | ||
| - | <div class="box_home_small"> | + | <div class="box_home_small" onClick="window.open('https://2011.igem.org/Team:Potsdam_Bioware/Project/Details#Modelling','_self');"> |
<h2>Modelling</h2></a> | <h2>Modelling</h2></a> | ||
Lorem ipsum dolor sit amet, consetetur sadipscing elitr, sed diam nonumy eirmod tempor invidunt ut labore et dolore magna aliquyam erat, sed diam voluptua. | Lorem ipsum dolor sit amet, consetetur sadipscing elitr, sed diam nonumy eirmod tempor invidunt ut labore et dolore magna aliquyam erat, sed diam voluptua. | ||
Revision as of 14:07, 18 September 2011
Project
One key task of biopharmaceuticals is the binding and blocking of deregulated proteins. Towards this goal, we mutate and select microviridins, which are tricyclic depsipeptides from cyanobacteria. They are small but stable due to their post-translational side-chain crosslinking. Microviridins have a high potential for therapy as they can block disease-relevant proteases. Yet, the possibilities of cyclic peptides are largely untapped since genetic systems for optimization are not well established. Thus, we developed synthetic systems for the mutation, selection and production of such peptides. We use the 6.5 kb microviridin (mdn) gene cluster cloned in E. coli plasmids, established random mutagenesis and generated focused libraries of microviridins. For selection against a panel of proteases, we are applying and testing phage display, and we are constructing a novel in-vivo selection device, which links protease blocking to antibiotic resistance. Our systems, including the 6.5 kb cluster, adhere to the BioBrick standards.
Software
Lorem ipsum dolor sit amet, consetetur sadipscing elitr, sed diam nonumy eirmod tempor invidunt ut labore et dolore magna aliquyam erat, sed diam voluptua. At vero eos et accusam et justo duo dolores et ea rebum. Stet clita kasd gubergren. [more]
Team
Nicole Albrecht
Katharina Berger
Nadja Bjelopoljak
Nadine Boehmer
Vanessa Boehmer
Jessica Eger
Steffi Sempert
Niels Weisbach
Sebastian Hanke
Sascha Ramm
-
Niels Weisbach
Paul Kaufmann
Stefan Wahlefeld
Sandrina Heyde
Sabine Meyer
Niklas Laasch
Oliver Zimmer
Tobias Wenzel
BioBricks
Lorem ipsum dolor sit amet, consetetur sadipscing elitr, sed diam nonumy eirmod tempor invidunt ut labore et dolore magna aliquyam erat, sed diam voluptua.[more]
Human Practice
Lorem ipsum dolor sit amet, consetetur sadipscing elitr, sed diam nonumy eirmod tempor invidunt ut labore et dolore magna aliquyam erat, sed diam voluptua. [more]
Labjournal
Lorem ipsum dolor sit amet, consetetur sadipscing elitr, sed diam nonumy eirmod tempor invidunt ut labore et dolore magna aliquyam erat, sed diam voluptua.[more]
Modelling
Lorem ipsum dolor sit amet, consetetur sadipscing elitr, sed diam nonumy eirmod tempor invidunt ut labore et dolore magna aliquyam erat, sed diam voluptua. [more]
